Anxiety Over Prospects For Legislative 510(k) Reform Appears To Be Growing

FDA and industry are concerned Congress will revise the 510(k) process and defended the program and warned against statutory reforms during a panel discussion at the Food and Drug Law Institute annual meeting in Washington, D.C